Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | CCR6 | P51684 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.60 |
| ▸ | APLNR | P35414 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364515 | 0.83 | ALDH1A1 (0.54) | KDM4ELMNASMN1; SMN2ALOX12RAB9A | |
| SCHEMBL18838386 | 0.83 | ALDH1A1 (0.54) | KDM4ELMNASMN1; SMN2ALOX12RAB9A | |
| SCHEMBL28823005 | 0.78 | KDM4E (0.83) | KDM4ELMNASMN1; SMN2OPRK1CCR6 | |
| SCHEMBL22594333 | 0.77 | KDM4E (0.78) | KDM4ELMNASMN1; SMN2OPRK1CCR6 | |
| SCHEMBL26665246 | 0.76 | KDM4E (0.78) | KDM4ELMNASMN1; SMN2OPRK1CCR6 | |
| SCHEMBL8266868 | 0.76 | RAB9A (0.77) | KDM4ELMNASMN1; SMN2RAB9ATP53 | |
| SCHEMBL15524115 | 0.76 | KDM4E (0.65) | KDM4ELMNASMN1; SMN2OPRK1CCR6 | |
| SCHEMBL26665270 | 0.75 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2OPRK1CCR6 | |
| SCHEMBL30656644 | 0.74 | KDM4E (0.77) | KDM4ELMNASMN1; SMN2OPRK1CCR6 | |
| SCHEMBL18838447 | 0.74 | KDM4E (0.64) | KDM4ELMNASMN1; SMN2OPRK1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3340988-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | Afasci, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KDM4E 2152/4885LMNA 3551/4885SMN1; SMN2 513/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | KDM4E 2152/4885LMNA 3551/4885SMN1; SMN2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.